Prediction of Thorough QT Trials based on Population Pharmacokinetic: Pharmacodynamic Analysis of Phase I Study QT Data

被引：0
|
作者：
Trame, Mirjam N.
Vik, Torbjorn [1 ,2 ]
Hamren, Ulrika Wahlby [3 ]
Henriksson, Karin M. [4 ,5 ]
Friberg, Lena E.
机构：
[1] Uppsala Univ, Pharmacometr Res Grp, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] AstraZeneca R&D, AZ ECG Ctr, Molndal, Sweden
[3] AstraZeneca R&D, Clin Pharmacol & Pharmacometr, Molndal, Sweden
[4] Dept Med Sci, Uppsala, Sweden
[5] AstraZeneca R&D, Dept Epidemiol, Molndal, Sweden
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetic/Pharmacodynamic Modeling to Support A Lack of Effect of Tafenoquine (TQ) on the QT Interval in a Thorough QT (TQT) Study
    Patel, Bela
    Miller, Ann
    Tenero, David
    Green, Justin
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S8 - S8
  • [2] Population Exposure-Response Analysis for an Escitalopram Thorough QT Study
    Khariton, Tatiana
    Carrothers, Timothy J.
    Periclou, Antonia
    Lindbom, Lars
    Ghahramani, Parviz
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S64 - S65
  • [3] SUBJECTS IN A POSITIVE THOROUGH QT STUDY RESPOND SIMILARLY TO MOXIFLOXACIN AND TWO DOSES OF STUDY DRUG: IS THIS A PHARMACOKINETIC OR A PHARMACODYNAMIC RESPONSE?
    Panicker, G. K.
    Kerkar, V
    Natekar, M.
    Karnad, D. R.
    Kothari, S.
    Narula, O.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1112 - 1112
  • [4] Bayesian Approach to Assay Sensitivity Analysis of Thorough QT Trials
    Dong, Xiaoyu
    Ding, Xiao
    Tsong, Yi
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (01) : 73 - 81
  • [5] CONCENTRATION-QT ANALYSIS IN THE PRESENCE OF PHARMACOKINETIC AND/OR PHARMACODYNAMIC INTERACTION
    Zhu, H.
    Wang, Y.
    Garnett, C.
    Gobburu, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S31 - S31
  • [6] Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies
    Florian, Jeffry A.
    Tornoe, Christoffer W.
    Brundage, Richard
    Parekh, Ameeta
    Garnett, Christine E.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (08): : 1152 - 1162
  • [7] Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
    Wang, Xiaoxing
    Gupta, Pankaj
    Malhotra, Bimal K.
    Farooqui, Saleem Ashley
    Le, Vu H.
    Wojciechowski, Jessica
    Mukherjee, Arnab
    Nicholas, Timothy
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1036 - 1045
  • [8] Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?
    Shah, Rashmi R.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 347 - 358
  • [9] Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials
    Yang, Haichen
    Laurenza, Antonio
    Williams, Betsy
    Patten, Anna
    Hussein, Ziad
    Ferry, Jim
    [J]. EPILEPSY RESEARCH, 2015, 114 : 122 - 130
  • [10] PERFORMANCEOF SEQUENTIAL AND SIMULTANEOUS PK/PD MODELING OF QT INTERVALS WITH PHASE I STUDIES TO PREDICT THOROUGH QT STUDY OUTCOMES.
    Lu, J.
    Al-Huniti, N.
    Helmlinger, G.
    Li, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S18 - S19
12345